Drugs / Simustine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06984536 Background | May → Jul 2025 overdue | acute leukemia, myelodysplastic syndrome | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06682130 Background | Nov 2024 → Nov 2027 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | simustine | “Simustine 250mg/m2 orally, day1” NCT06682130 ↗1“simustine (250 mg/m2, day -3)” NCT06984536 ↗ |
| Route | Oral | “Simustine 250mg/m2 orally, day1” NCT06682130 ↗ |